Valsartan is an angiotensin II antagonist belonging to class II BCS, its low aqueous solubility leads to high variability in its absorption after oral administration. The aim of this study was to improve the dissolution of Valsartan through the development of solid self nano-emulsifying drug delivery systems (S-SNEDDS) using melting technique. For this purpose, four different oils namely; Capmul® MCM, Labrafil® M1944, Capryol™ 90 and Labrafac® PG were used together with Cremophor® RH 40 as surfactant which was screened previously according to its ability to emulsify the oil. Solidifying agents namely; PEG 4000 and Pluronic® F-68 were screened according their ability to solidify the different oil-surfactant mixtures. The effect of solidifying agent type on the in-vitro valsartan dissolution (Q5min) was studied. Characterization of the prepared S-SNEDDS was also carried out via content uniformity, DSC and FT-IR. Formula S6 prepared using Labrafil® M 1944 as oil and Cremophore® RH40 as surfactant in a ratio of (1:2) together with Pluronic® F68 (40% w/w) as solidifying agent showed promising results in terms of dissolution studies where 58.39%±1.88 of valsartan was dissolved compared to the market Disartan 80 mg capsules (13.43%±0.57). Content uniformity complied with the Pharmacopoeial limit. The disappearance of endothermic valsartan peak in the DSC thermogram suggested its conversion to amorphous form within the prepared S-SNEDDS. Compatibility of valsartan with the different excipients was confirmed using FT-IR. Therefore, S-SNEDDS could be considered as a promising approach to improve the dissolution of the poorly water soluble, valsartan.
Loading....